Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae
about
What's new in multidrug-resistant pathogens in the ICU?Evaluation of biophotonic imaging to estimate bacterial burden in mice infected with highly virulent compared to less virulent Streptococcus pneumoniae serotypes.Dendritic cell depletion and repopulation in the lung after irradiation and bone marrow transplantation in mice.C-type Lectin Mincle Recognizes Glucosyl-diacylglycerol of Streptococcus pneumoniae and Plays a Protective Role in Pneumococcal PneumoniaTNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice.Advances in MRSA drug discovery: where are we and where do we need to be?A current perspective on daptomycin for the clinical microbiologist.Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy.Current use of daptomycin in cardiac surgery and postoperative intensive care.FMS-like tyrosine kinase 3 ligand treatment of mice aggravates acute lung injury in response to Streptococcus pneumoniae: role of pneumolysin.Cathepsin G and neutrophil elastase play critical and nonredundant roles in lung-protective immunity against Streptococcus pneumoniae in mice.Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.Local delivery of GM-CSF protects mice from lethal pneumococcal pneumonia.Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol.
P2860
Q28071346-35419F5B-4758-41D5-9FC5-A3E6AEA460BDQ34045214-AE9D905B-83BA-4477-872C-B3D84F037B3CQ35991269-65358B27-7B30-4F6D-A64A-17C2D7B92ED1Q36214308-9B1D82DF-9498-4136-8608-A8FEA4F4CD4AQ36340830-CCA86A24-AD55-4946-A397-A860EC64DAC4Q37112508-A4EE98C6-93D6-471F-95F0-0070A02DE45EQ37263289-D980FEA5-6521-47F9-A9B2-C2F2D16E17FCQ37821604-BA7622C5-C657-436D-9751-58800FAD0A41Q38086339-314AE682-CA31-4F16-9320-540562094F32Q38923919-FD8EE6DC-0A86-4ED5-9261-2BDB98CBC46AQ39656294-7EA3F775-AF95-4F96-B2A0-F4A3C82F079AQ40066351-CF056989-52FD-4CF3-8F98-5E11DDFD3A5AQ41241667-DCC74338-C031-413D-9D61-90825494DF14Q42019910-A337AD47-36FD-49F9-88E3-537B7EB65C56
P2860
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy profiles of daptomyci ...... with Streptococcus pneumoniae
@ast
Efficacy profiles of daptomyci ...... with Streptococcus pneumoniae
@en
Efficacy profiles of daptomyci ...... with Streptococcus pneumoniae
@nl
type
label
Efficacy profiles of daptomyci ...... with Streptococcus pneumoniae
@ast
Efficacy profiles of daptomyci ...... with Streptococcus pneumoniae
@en
Efficacy profiles of daptomyci ...... with Streptococcus pneumoniae
@nl
prefLabel
Efficacy profiles of daptomyci ...... with Streptococcus pneumoniae
@ast
Efficacy profiles of daptomyci ...... with Streptococcus pneumoniae
@en
Efficacy profiles of daptomyci ...... with Streptococcus pneumoniae
@nl
P2093
P2860
P3181
P356
P1476
Efficacy profiles of daptomyci ...... with Streptococcus pneumoniae
@en
P2093
David E Briles
Dirk Wedekind
Franz C Bange
James C Paton
Jennifer Bohling
Jens Martens-Lobenhoffer
Stefanie Henken
Thomas Welsh
Tobias Welte
Ulrich A Maus
P2860
P304
P3181
P356
10.1128/AAC.00943-09
P407
P577
2009-11-16T00:00:00Z